Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Gilead Sciences will pay 21 billion dollars to acquire Immunomedics and gain control of Trodelvy, a recently approved antibody-drug conjugate for metastatic…
Gilead Sciences agreed to acquire cancer-drug developer Immunomedics for 21 billion dollars in cash, the U.S. drugmaker's biggest deal yet, to bolster its…
Gilead's $21 billion purchase of Immunomedics boosts ADC field. The deal gives Gilead Trodelvy, a recently approved antibody-drug conjugate, and a platform for…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Gilead Sciences acquired Immunomedics for approximately $21 billion ($88.00 per share in cash), a 108% premium, gaining Trodelvy (sacituzumab govitecan), the first FDA-approved anti-Trop-2 antibody-drug conjugate for metastatic triple-negative breast cancer, along with Immunomedics' proprietary ADC platform technology.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Immunomedics Inc. (this deal) | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
| Gilead Sciences Inc. / Myogen Inc. | 2006 | $2.5B | 62 |
← Browse all deals · How we score deals
More: 2020 deals · Gilead Sciences Inc. deals · Oncology deals